Analysis of the idiotypic network in tumor immunity.
Open Access
- 1 December 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 139 (11) , 3902-3910
- https://doi.org/10.4049/jimmunol.139.11.3902
Abstract
Herein we have analyzed the expression of idiotopes associated with a monoclonal anti-tumor-associated antigen (TAA) antibody in DBA/2 mice which have progressively growing tumors or resist tumor growth. A panel of eight monoclonal antiidiotypic antibodies raised against a monoclonal antibody which reacts with a mouse mammary tumor virus cross-reactive qp52 envelope protein (TAA) of the L1210/GZL lymphoma was used to measure the expression of idiotopes in sera from different treatment groups. Significant correlations between the expression of certain idiotopes and the growth of the tumor or the establishment of anti-tumor immunity are seen. 1) Idiotypes detected by anti-idiotype D11 are high in anti-idiotype immunized progressor or tumor-susceptible mice and low or absent in regressor mice, i.e., the mice immunized with the protective 2F10 anti-idiotype; 2) the 3A4-detected idiotypes are less frequent or absent in irradiated tumor-immunized regressor mice than in untreated mice challenged with live tumor or progressor mice; 3) no difference in the anti-TAA titers is seen in mice in which the tumor growth is inhibited and in mice in which the tumor grows; 4) no difference in 11C1 idiotype + anti-TAA titer was observed between regressor and progressor mice; and 5) mice with normal or accelerated tumor growth have higher titers of idiotypes detected by a polyclonal anti-idiotype. These findings provide evidence for a regulatory idiotype network induced by the growing L1210/GZL tumor or by anti-idiotypic immunization. The titer of anti-TAA antibody does not correlate with the biology of tumor growth, but certain idiotopes correlate with either progressive or regressive tumor behavior. Therefore, the target of the idiotype regulation is likely to be anti-tumor T effector cells. Effective idiotype therapy of tumors must deal with the complexity of idiotype regulation induced by the tumor itself and is unlikely to be successful if anti-idiotypes are used only as internal mimicry of a TAA.This publication has 22 references indexed in Scilit:
- Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.Proceedings of the National Academy of Sciences, 1984
- Antibody to Hepatitis B Virus Induced by Injecting Antibodies to the IdiotypeScience, 1984
- Induction of suppressor T cells by monoclonal anti-idiotope antibody in strains of mice not expressing the idiotope in hyperimmune serum.The Journal of Immunology, 1983
- DIFFERENTIAL ANTIGENIC EXPRESSION OF THE DBA/2 LYMPHOMA-L1210 AND ITS SUBLINES - CROSS-REACTIVITY WITH C3H MAMMARY-TUMORS AS DEFINED BY SYNGENEIC MONOCLONAL-ANTIBODIES1983
- Immune response to phosphorylcholine. IX. Characterization of hybridoma anti-TEPC15 antibodies.The Journal of Immunology, 1982
- Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: Possible application to vaccine productionClinical Immunology and Immunopathology, 1981
- Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones.The Journal of Experimental Medicine, 1981
- Suppression of tumor rejection by autologous anti-idiotypic immunityProceedings of the National Academy of Sciences, 1980
- Antigen- and receptor-driven regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotypic antibodies.The Journal of Experimental Medicine, 1979
- Idiotypic regulation of the immune system by the induction of antibodies against anti-idiotypic antibodies.Proceedings of the National Academy of Sciences, 1977